ESRRA and breast carcinoma: Here we explore the hypothesis that ERRα acts as an effector of mitogenic signalling responsible for metabolic adaptations of breast cancer cells and further provide evidence of its implication in the therapeutic response and resistance to the RTK inhibitor lapatinib.